External Counterpulsation May Improve Alzheimer's Cognitive Function
A new clinical trial shows non-invasive cardiac-synchronized therapy could help patients with early-stage Alzheimer's disease.
Updated on Oct. 30, 2026 in Alzheimer’s
Live Poll
Should non-invasive alternative therapies be integrated into standard treatment plans for Alzheimer's patients?
A 12-month randomized controlled trial involving 190 participants with early Alzheimer's disease found that external counterpulsation therapy can improve cognitive performance. Patients who received the sessions showed measurable progress in memory, attention, language, and reasoning.
Why it matters
The study suggests that by synchronizing inflatable cuffs with the cardiac cycle, the therapy improves brain blood flow and reduces inflammation while clearing toxic proteins. This non-invasive approach offers a potential new avenue for managing cognitive decline in early-stage patients.
The clinical trial followed 190 participants over a 12-month duration to track cognitive improvements after receiving 35 initial external counterpulsation sessions. Researchers observed better outcomes in memory and daily task performance compared to the study baseline.
The players
American Journal of Alzheimer's Disease & Other Dementias
This peer-reviewed medical publication serves as a leading source for research findings related to dementia and cognitive health.
Providence Saint John's Health Center
Located in Santa Monica, California, this medical facility is known for clinical excellence and ongoing neurological research.
Northwell Health
Headquartered in Westchester, New York, this health system operates extensive neurological departments and participates in large-scale clinical trials.
The details
The treatment uses specialized cuffs placed on the butt, calves, and thighs that inflate and deflate in time with the patient's heartbeat. Participants received up to five one-hour sessions weekly for the first phase, followed by twice-weekly treatments for the remainder of the study.
Timeline
The randomized controlled trial spanned 12 months.
Cognitive assessments occurred at weeks 6, 12, 18, 24, 36, and 52.
Health Landscape
This study is published in the American Journal of Alzheimer's Disease & Other Dementias and contributes to the growing body of literature on novel non-pharmacological interventions. It marks a departure from traditional drug-focused therapies by exploring how cardiovascular synchronization impacts neurodegeneration.
The study suggests that patients with early-stage Alzheimer's could eventually see new non-invasive treatment options that improve daily cognitive function. However, because the lead author is affiliated with the manufacturer, families should discuss the need for further clinical validation with their neurologists.
The takeaway
While these findings are promising for early-stage cognitive support, they currently represent early-stage research that requires broader confirmation. Patients should maintain standard care routines until larger trials determine the long-term feasibility and safety of this therapy.
Further reading
For more information on the latest research in this field, visit the Alzheimer’s section.
Source note: This article includes information reported by Women's Health.
Live Poll
Should non-invasive alternative therapies be integrated into standard treatment plans for Alzheimer's patients?
